Lonza, a major Swiss contract development and manufacturing organization, has appointed Daniel Palmacci as president of its Cell and Gene Division. He will take over the role from Jean-Christophe Hyvert, who will continue to serve as president of Lonza’s Biologics Division. 12 September 2022
US biotech Vertex Pharmaceuticals today announced that Jonathan Biller has been appointed chief legal officer, effective September 19, 2022. 8 September 2022
STORM Therapeutics, a UK biotech discovering and developing small molecule therapies targeting RNA modification enzymes for oncology and other diseases, has announced the appointment of Gerald McMahon as president, chief executive and board director. 7 September 2022
Nodus Oncology, a novel biotech company focused on developing first and best-in-class molecules inhibiting novel DNA damage response (DDR) targets, has launched with seed funding from Cumulus Oncology and announced a partnership with the Lead Discovery Center (LDC). 6 September 2022
The Drugs for Neglected Diseases initiative (DNDi) has announced Dr Luis Pizarro as its new executive director, who will replace Bernard Pécoul, who has served in the role for almost 20 years. 5 September 2022
A new chapter opens at privately-held Italian drugmaker Chiesi Farmaceutici as the 11-year tenure of chief executive Ugo Di Francesco, aged 62, comes to a close at the end of 2022. 5 September 2022
Private equity firm Permira, in partnership with the Marcucci family and supported by their co-investors, have completed the joint acquisition and combination of Kedrion Biopharma and Bio Products Laboratory (BPL). 1 September 2022
Ocugen, a US biotech focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, has announced the appointment of Robert Hopkins as chief medical officer (CMO) and Arun Upadhyay as chief scientific officer (CSO). 1 September 2022
Scandion Oncology, a Danish biotech developing medicines for treatment-resistant cancer, has announced that president and chief executive Bo Rode Hansen will leave his position with immediate effect by mutual agreement. 31 August 2022
Celsius Therapeutics, a privately-held biotech developing precision medicines for cancer and autoimmune disease through single-cell RNA sequencing, has named Sarah Grant its chief medical officer (CMO). 26 August 2022
As had long been expected, Novartis has announced plans to hive off its generics business, Sandoz, creating a new publicly-traded company. 25 August 2022
AstriVax, a start-up working to develop novel vaccines, has raised the largest amount of seed capital in the history of Belgium-based university KU Leuven spin-offs, totalling $30 million. 25 August 2022
British biotech Mereo BioPharma has revealed its largest shareholder is agitating to purge certain board members as part of a plan to change the firm’s strategic direction. 23 August 2022
Singapore-based Tessa Therapeutics, a Temasek-backed clinical stage biotech company, today announced the appointment of Thomas Willemsen as its president and chief executive, effective October 1, 2022. 22 August 2022
Privately-held North Carolina, USA-based contract research organization BioAgilytix has named Linda Robbie its new chief operating officer. 17 August 2022
PsiOxus, a clinical-stage biotechnology company developing a novel platform technology for the targeted delivery of therapeutic transgenes to solid tumors, has announced the appointment of its new chief executive, Howard Davis. 12 August 2022
California, USA-based Appia Bio, a pre-clinical-stage biotechnology company today announced that Jason Damiano has been appointed as its chief scientific officer. 10 August 2022
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024